IP Library Granted Patent US 10,150,769
Granted Patent B2
US 10,150,769 · App. 16/006,125 · Granted Dec 11, 2018

Spiro-lactam NMDA modulators and methods of using same

Inventor: M. Amin Khan (Evanston, IL)
Assignee: Aptinyx Inc.
C07D471/10A61K9/0019
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,150,769
App. No.
16/006,125
Granted
Dec 11, 2018
Kind
B2
Abstract

Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.

Claims (4)

1. A compound having the formula:

or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient.

3. The pharmaceutical composition of claim 2 , suitable for oral administration, parenteral administration, topical administration, intravaginal administration, intrarectal administration, sublingual administration, ocular administration, transdermal administration, or nasal administration.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 1, 2023
From: APTINYX INC.
To: TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED
Reel/Frame 065426/0673 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 27, 2018
From: KHAN, M. AMIN
To: APTINYX INC.
Reel/Frame 046212/0782 →
Continuity (4)
Continuation PCTUS2017044871 · Aug 1, 2017
Provisional Application 62443915 · Jan 9, 2017
Provisional Application 62369529 · Aug 1, 2016
Related Publication 20180291023A1 · Oct 11, 2018